Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.67 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.63 |
| ▸ | KYNU | Q16719 | 1/20 | 0.55 |
| ▸ | LAP3 | P28838 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2353877 | 0.88 | ELANE (0.72) | ELANEPRTN3KYNUATMECE1 | |
| SCHEMBL2353879 | 0.88 | ELANE (0.72) | ELANEPRTN3KYNUATMECE1 | |
| SCHEMBL6130888 | 0.87 | ELANE (0.61) | ELANEPRTN3KYNUATMECE1 | |
| SCHEMBL6923368 | 0.86 | KYNU (0.57) | ELANEPRTN3KYNULAP3ATM | |
| SCHEMBL6923362 | 0.86 | KYNU (0.57) | ELANEPRTN3KYNULAP3ATM | |
| SCHEMBL6130869 | 0.86 | ELANE (0.63) | ELANEPRTN3ATMECE1ACE2 | |
| SCHEMBL7397375 | 0.82 | ECE1 (0.59) | KYNULAP3ECE1ACE2MME | |
| SCHEMBL14981588 | 0.82 | ALDH1A1 (0.56) | ELANEPRTN3KYNULAP3ATM | |
| SCHEMBL9970972 | 0.81 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL9152554 | 0.80 | ELANE (0.62) | ELANEPRTN3KYNUATMECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | ELANE 789/4885PRTN3 1152/4885KYNU 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.